FAQ
Log In
Monday 23rd April 2018
News
 › 
 › 

NICE rejects breast cancer drug

9th July 2010

The National Institute for Health and Clinical Excellence has not approved the use of Avastin to treat breast cancer.

NICE said the drug, known as bevacizumab, was not suitable for use in patients whose cancer had metasised because of "uncertain evidence". "The clinical trial results for bevacizumab were disappointing in that they were unable to prove definitively that the drug could extend the lives of patients with metastatic breast cancer over and above currently available treatments," said NICE Chief Executive Andrew Dillon.

Share this page

Comments

There are no comments for this article, be the first to comment!


Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Article Information

Title: NICE rejects breast cancer drug
Author: Jess Laurence
Article Id: 15444
Date Added: 9th Jul 2010

Sources

Reuters News

Recent Related Articles

Prescription drug addiction to be reviewed

Actions

Add to scrapbook
Show Comments
Add comment
Find all related articles

Tags

M3 - For secure managed hosting over N3 or internet
© Mayden Foundation 2018